MediciNova (MNOV) Competitors $1.54 +0.05 (+3.36%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. AURA, ATAI, GLUE, SEPN, PVLA, ATYR, TSHA, TSVT, ALMS, and AVIRShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Aura Biosciences (AURA), Atai Life Sciences (ATAI), Monte Rosa Therapeutics (GLUE), Septerna (SEPN), Palvella Therapeutics (PVLA), Atyr PHARMA (ATYR), Taysha Gene Therapies (TSHA), 2seventy bio (TSVT), Alumis (ALMS), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Aura Biosciences Atai Life Sciences Monte Rosa Therapeutics Septerna Palvella Therapeutics Atyr PHARMA Taysha Gene Therapies 2seventy bio Alumis Atea Pharmaceuticals MediciNova (NASDAQ:MNOV) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Does the MarketBeat Community prefer MNOV or AURA? MediciNova received 187 more outperform votes than Aura Biosciences when rated by MarketBeat users. However, 61.90% of users gave Aura Biosciences an outperform vote while only 47.33% of users gave MediciNova an outperform vote. CompanyUnderperformOutperformMediciNovaOutperform Votes21347.33% Underperform Votes23752.67% Aura BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% Which has better valuation & earnings, MNOV or AURA? MediciNova has higher revenue and earnings than Aura Biosciences. MediciNova is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1M75.53-$8.56M-$0.23-6.70Aura BiosciencesN/AN/A-$76.41M-$1.75-3.15 Is MNOV or AURA more profitable? MediciNova's return on equity of -19.66% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -19.66% -18.63% Aura Biosciences N/A -41.57%-36.43% Does the media favor MNOV or AURA? In the previous week, Aura Biosciences had 5 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Aura Biosciences and 0 mentions for MediciNova. Aura Biosciences' average media sentiment score of 1.29 beat MediciNova's score of 0.59 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Overall Sentiment MediciNova Positive Aura Biosciences Positive Do institutionals & insiders believe in MNOV or AURA? 9.9% of MediciNova shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 14.9% of MediciNova shares are owned by company insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, MNOV or AURA? MediciNova has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Do analysts rate MNOV or AURA? MediciNova presently has a consensus target price of $9.00, indicating a potential upside of 484.42%. Aura Biosciences has a consensus target price of $22.75, indicating a potential upside of 312.14%. Given MediciNova's higher probable upside, equities research analysts clearly believe MediciNova is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryMediciNova beats Aura Biosciences on 9 of the 17 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.53M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-6.707.0522.2318.31Price / Sales75.53273.45398.02107.04Price / CashN/A65.6738.2034.62Price / Book1.446.506.824.25Net Income-$8.56M$142.50M$3.20B$247.51M7 Day Performance6.21%8.32%5.78%6.86%1 Month Performance4.76%-5.61%-4.31%-2.95%1 Year Performance16.67%0.11%17.88%5.17% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova1.3843 of 5 stars$1.54+3.4%$9.00+484.4%+13.7%$75.53M$1M-6.7010Analyst ForecastNews CoverageGap UpAURAAura Biosciences2.3263 of 5 stars$5.45+2.8%$22.75+317.4%-22.3%$273.73MN/A-3.1550Positive NewsATAIAtai Life Sciences2.1889 of 5 stars$1.38+7.0%$10.50+660.9%-18.2%$273.66M$308,000.00-1.7080Positive NewsGap UpGLUEMonte Rosa Therapeutics2.977 of 5 stars$4.41+4.5%$15.50+251.5%-4.6%$271.26M$75.62M-2.4190Positive NewsSEPNSepterna2.0645 of 5 stars$6.07+6.1%$33.00+443.7%N/A$269.76M$1.08M0.00N/ALockup ExpirationPositive NewsPVLAPalvella Therapeutics3.4723 of 5 stars$24.44+12.3%$44.43+81.8%N/A$269.30M$42.81M-2.02N/AATYRAtyr PHARMA2.4102 of 5 stars$3.01+1.3%$18.60+517.9%N/A$267.47M$235,000.00-3.2053Upcoming EarningsTSHATaysha Gene Therapies3.2263 of 5 stars$1.28+2.8%$6.63+417.6%-22.6%$262.40M$8.33M2.03180Positive NewsTSVT2seventy bio2.1978 of 5 stars$4.96flat$5.60+12.9%+16.9%$259.60M$37.86M-2.67440Upcoming EarningsAnalyst ForecastALMSAlumis2.3513 of 5 stars$5.39-16.8%$26.00+382.4%N/A$254.53MN/A0.00N/AAnalyst ForecastAnalyst RevisionAVIRAtea Pharmaceuticals2.7266 of 5 stars$2.94+8.5%$6.00+104.1%-22.4%$251.44MN/A-1.4270 Related Companies and Tools Related Companies AURA Competitors ATAI Competitors GLUE Competitors SEPN Competitors PVLA Competitors ATYR Competitors TSHA Competitors TSVT Competitors ALMS Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
